Lunit Raises $61M in Pre-IPO Funding


Lunit, a Seoul, South Korea-based medical AI company, raised $61M in Pre-IPO funding.

Backers included HealthQuest Capital (which invested $20m), Casdin Capital, American Cancer Society BrightEdge, Tybourne Capital Management and NSG Ventures. Following the most recent strategic investment of $26m from Guardant Health, the company has now secured more than $135 million in total ahead of its planned KOSDAQ IPO next year 

Led by Brandon Suh, CEO, Lunit develops AI-powered diagnostic tools for cancer screening, as well as biomarkers that can accurately predict and guide which patients respond to specific cancer therapy. Its radiology solutions for chest x-ray and mammography, Lunit INSIGHT, in active partnership with various medical device companies including GE Healthcare, Philips, and FujiFilm, is available in 30+ countries and will also be offered in the US given the recent FDA approval.